Proactive communication and leveraging advanced, yet reliable, technologies to maximize efficiency are essential pillars of success.
Retina is a rapidly advancing field with promising research, technology, and treatment areas. Two stand out as particularly exciting.
The use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.
Real-world evidence is growing in importance as a source of information that can help support clinical decision-making when evaluated properly.
The use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.
Results from expert surveys provide snapshots of our understanding of DME and shed light on where the 0.19-mg FAc implant stands in the current standard of care.
In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.
Sujay Jadhav, CEO of Verana Health, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), provides an overview of new FDA guidance.
Current options, challenges in developing novel therapies.
A retina specialist shares his presentation from the 2023 ASRS Annual Meeting, which describes a study comparing the efficacy of 2 FDA-approved treatments for geographic atrophy based on an anchored matching-adjusted indirect comparison of phase 3 trial findings.
The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”
Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.
This article is produced by Roche for healthcare professionals and is not intended to provide medical advice and/or treatment guidance. This website is not country-specific and therefore may contain information which is not applicable to your country.
Knowledge of tools used in data interpretation helps clinicians trust accuracy of findings.
Technology brings new tools to those with low vision caused by AMD
A key distinction between patients seen in the clinic vs those enrolled in clinical trials has to do with characteristics dictated by the trial’s inclusion/exclusion criteria.
While operating on a patient with chronic uveitis presents some challenges, there are a few pearls that may increase success.
Experts conclude the series with the hope that longer-acting agents will lead to better real-world outcomes for patients, mirroring clinical trial results and potentially preventing vision loss, especially in countries with limited access to healthcare.
Clinical benefit of complement inhibition has been demonstrated in clinical trials, but there are possible consequences to consider.
The agency approved Yesafili (Biocon Biologics) and Opuviz (Samsung Bioepis, Biogen) as biosimilars to Eylea (Regeneron Pharmaceuticals).
Minimizing clinic visits, maximizing use of imaging modalities are key
The plan is intended to upgrade Vitagrus’ manufacturing process so that it can ultimately handle the global market supply.
Nonetheless,BDUMP remains a rare condition with fewer than 60 cases documented in literature.
A multifaceted evaluation that includes ultra-widefield imaging can reveal new information and influence treatment decisions.
Easier, more accessible functional studies have been made possible